A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Akdis, C. A., Akdis, M., Bieber, T., Bindslev‐Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01153.x · Cited by 733
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04636.x · Cited by 360
Roekevisch, E., Spuls, P. I., Kuester, D., Limpens, J., & Schmitt, J. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.049 · Cited by 322
Guidelines for management of atopic dermatitis
SAEKI, H., FURUE, M., FURUKAWA, F., HIDE, M., OHTSUKI, M., KATAYAMA, I., SASAKI, R., SUTO, H., TAKEHARA, K., & COMMITTEE for GUIDELINES for the MANAGEMENT of ATOPIC DERMATITIS of JAPANESE DERMATOLOGICAL ASSOCIATION (2009) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2009.00706.x · Cited by 265
Lyons, J. J., Milner, J. D., & Stone, K. D. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.09.008 · Cited by 228 · cited 4×
“BDP resulted in a 22% decrease in mean AD severity using an unvalidated outcome, lower parent-assessed overall disease activity, and greater treatment preference toward BDP.(10,11) Oral BDP, 600 g 3 times daily for 4 weeks followed by 1000 g daily for 6 weeks, improved disease activity in 14 of 15 children with severe…”
BackgroundMethodInfluentialSystemic Treatment of Severe Atopic Eczema: A Systematic Review
Schmitt, J., Schäkel, K., Schmitt, N., & Meurer, M. (2007) · Acta Dermato-Venereologica · doi:10.2340/00015555-0207 · Cited by 141
Schmitt, J., Schäkel, K., Fölster-Holst, R., Bauer, A., Oertel, R., Augustin, M., Aberer, W., Luger, T., & Meurer, M. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09561.x · Cited by 135 · cited 1×
“Systemic therapy is recommended for persistent, moderate-to-severe AD after inadequate response to optimized topical management.(2) A wide range of treatment strategies have been used for systemic corticosteroids (SCSs) in clinical practice (eg, different deliveries, dosing, frequencies, and durations).”
BackgroundBarnetson, R. S., & Rogers, M. (2002) · BMJ · doi:10.1136/bmj.324.7350.1376 · Cited by 126 · cited 1×
“A systematic review of adrenal insufficiency (AI) (cortisol level, #500 nmol/L) after glucocorticoid use identified 74 articles with 3753 participants with various medical diagnoses.(22) Specific doses varied depending on steroid choice (Supplemental Table II).”
BackgroundAtopic dermatitis in older patients: particular points: Particular points of atopic dermatitis
Katsarou, A., & Armenaka, M. (2011) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03737.x · Cited by 121 · cited 1×
“A retrospective case-control study of 112 patients with rheumatoid arthritis who were or were not taking long-term, low-dose (\15 mg/d) prednisone for more than 1 year found higher rates of AEs in the prednisone group.(33) AEs included fractures, cataracts, serious infections, and gastrointestinal bleeds and/or ulcers.”
BackgroundConsensus guidelines for the management of atopic dermatitis: An A sia– P acific perspective
Rubel, D. M., Thirumoorthy, T., Soebaryo, R. W., Weng, S. C. K., Gabriel, M. T., Villafuerte, L. L., Chu, C., Dhar, S., Parikh, D., Wong, L.-C. F., et al. (2013) · The Journal of Dermatology · doi:10.1111/1346-8138.12065 · Cited by 118
The European treatment of severe atopic eczema in children taskforce (TREAT) survey
Proudfoot, L. E., Powell, A. M., Ayis, S. A., Barbarot, S., Baselga, E., Deleuran, M. S., Fölster‐Holst, R., Gelmetti, C., Hernández‐Martín, A., Middelkamp-Hup, M. A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12505 · Cited by 117
Systemic therapy for atopic dermatitis
Simon, D., & Bieber, T. R. M. (2013) · Allergy · doi:10.1111/all.12339 · Cited by 112
Atopic dermatitis in older adults: A viewpoint from geriatric dermatology
Tanei, R., & Hasegawa, Y. (2016) · Geriatrics & Gerontology International · doi:10.1111/ggi.12771 · Cited by 102 · cited 1×
“Alternate-day dosing using an intermediate-acting steroid (eg, prednisone) may allow approximately 12 hours of hypothalamicpituitary-adrenal axis recovery on the off day.(7) However, risk for osteoporosis, cataracts, and growth-retardation is related to cumulative steroid dosing and is not mitigated by this dosing reg…”
BackgroundSystemic therapy of atopic dermatitis
Sidbury, R., & Hanifin, J. M. (2000) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2000.00697.x · Cited by 92
Atopic dermatitis: a review of diagnosis and treatment.
Correale, C. E., Walker, C., Murphy, L., & Craig, T. (1999) · PubMed · Cited by 88
Systemic therapy of atopic dermatitis
Bußmann, C., & Novak, N. (2017) · Allergologie select · doi:10.5414/alx01285e · Cited by 80
House dust mite reduction and avoidance measures for treating eczema
Nankervis, H., Pynn, E. V., Boyle, R. J., Rushton, L., Williams, H. C., Hewson, D. M., & Platts-Mills, T. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008426.pub2 · Cited by 79
Minimizing Complications from Systemic Glucocorticosteroid Use
Nesbitt, L. T. (1995) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30055-x · Cited by 77
The Diagnosis and Graded Therapy of Atopic Dermatitis
Werfel, T., Schwerk, N., Hansen, G., & Kapp, A. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0509 · Cited by 77 · cited 13×
“However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD.”
BackgroundInfluentialTherapeutic options in the treatment of psoriasis and atopic dermatitis
Gottlieb, A. B. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.04.026 · Cited by 75 · cited 6×
“An observational study reported that no patients showed signs or symptoms of AI from IM TAC for various dermatoses.(20) Total cortisol level decreased significantly at 6 and 12 weeks versus baselinewith IM TAC, butmeanmorning cortisol and ACTH levels did not differ significantly.”
BackgroundMethodInfluentialSystemic therapies for severe atopic dermatitis in children and adults
Flohr, C., & Irvine, A. D. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.016 · Cited by 61
Atopic Dermatitis: an Update and Review of the Literature
Lipozenčić, J., & Wolf, R. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.06.009 · Cited by 59
Managing childhood atopic dermatitis
Leung, A. K. C., & Barber, K. A. (2003) · Advances in Therapy · doi:10.1007/bf02850199 · Cited by 59 · cited 1×
“A retrospective cohort study of 1,548,945 adults from a nationwide data set of private insurance claims found that short-term use of oral corticosteroids for fewer than 30 days for any indication was associated with increased rates of sepsis, venous thromboembolism, and fracture.(31) Another Cochrane review assessed t…”
BackgroundWolter, S., & Price, H. N. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2013.11.002 · Cited by 58
Systemic Therapy of Atopic Dermatitis in Children
Ricci, G., Dondi, A., Patrizi, A., & Masi, M. (2009) · Drugs · doi:10.2165/00003495-200969030-00005 · Cited by 55 · cited 12×
“However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD.”
BackgroundInfluentialAtopic Dermatitis: Systemic Immunosuppressive Therapy
Akhavan, A., & Rudikoff, D. (2008) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2008.04.004 · Cited by 48
Systemic therapeutic options for severe atopic dermatitis
Bußmann, C., Bieber, T. R. M., & Novak, N. (2008) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2008.06834.x · Cited by 44 · cited 3×
“However, risk for osteoporosis, cataracts, and growth-retardation is related to cumulative steroid dosing and is not mitigated by this dosing regimen.(8,25,28) No studies evaluating the impact of short-term subclinical HPA access suppression were identified.”
BackgroundDifficult to control atopic dermatitis
Darsow, U. G., Wollenberg, A., Simon, D., Taïeb, A., Werfel, T., Oranje, A. P., Gelmetti, C. M., Svensson, Å., Deleuran, M. S., Calza, A., et al. (2013) · World Allergy Organization Journal · doi:10.1186/1939-4551-6-6 · Cited by 44
What is new in atopic dermatitis/eczema?
Plötz, S. G., Wiesender, M., Todorova, A., & Ring, J. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.953927 · Cited by 41 · cited 1×
“Flunisolide, a synthetic steroid analogue, was orally administered to 20 children (640 g/d in children age \3 years and 1200 g/d in older children) and resulted in a 49% reduction of clinical severity scores versus those with placebo after 2 weeks.(10,13) After the crossover portion at week 3, there was no significant…”
BackgroundSystemic Therapy of Atopic Dermatitis in Children and Adults
Simon, D. (2011) · Current problems in dermatology · doi:10.1159/000323309 · Cited by 32 · cited 1×
“Finally, a Cochrane review found that regular use of inhaled corticosteroids was associated with significant growth suppression measured by linear growth velocity in children with mild-to-moderate persistent asthma.(34) Growth suppression appeared to be maximal during the first year of therapy.”
BackgroundEczema therapeutics in children: what do the clinical trials say?
Leung, T. N., & Hon, K. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144474 · Cited by 31
Therapeutic Perspectives in Atopic Dermatitis
Misery, L. (2010) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8226-y · Cited by 31 · cited 20×
“However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD.”
BackgroundResultInfluentialSystemic Agents for Severe Atopic Dermatitis in Children
Notaro, E., & Sidbury, R. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0150-4 · Cited by 27 · cited 13×
“However, few studies have assessed the safety and efficacy of systemic corticosteroids in AD.”
BackgroundInfluentialAtopic dermatitis. A clinical challenge.
Turner, J. D., & Schwartz, R. A. (2006) · PubMed · Cited by 27
Childhood Atopic Dermatitis in Taiwan
Wang, I., Wang, J., & Yeh, K. (2015) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2015.08.005 · Cited by 25 · cited 2×
“Intravenous methylprednisolone, 20 mg/kg/d administered for 3 consecutive days, resulted in immediate improvement of skin lesions and pruritus in 5 of 7 children.(16) Symptom relapse occurred after 3 to 18 months.”
BackgroundReddy, S. B., Ananthakrishnan, S., & Garg, A. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.02.005 · Cited by 25
Pediatric Atopic Dermatitis: A Review of the Medical Management
Carbone, A. M., Siu, A., & Patel, R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p098 · Cited by 25 · cited 1×
“SCSs may be a useful treatment of AD flares owing to their rapid induction of a clinical response, perceived short-term safety and tolerability, and low cost.(6) However, few studies have assessed the efficacy and safety of SCSs in AD.”
BackgroundSteinke, S., Langenbruch, A. K., Ständer, S., Franzke, N., & Augustin, M. (2014) · Dermatology · doi:10.1159/000358587 · Cited by 24
Short stature in children with atopic eczema.
David, T. J. (1989) · PubMed · doi:10.2340/000155551444144 · Cited by 23
Recent Advances in Treatment Strategies for Atopic Dermatitis
Roos, T. C., Geuer, S., Roos, S., & Brost, H. (2004) · Drugs · doi:10.2165/00003495-200464230-00003 · Cited by 23 · cited 1×
“A case series of 3 patients with severe AD successfully treated with SCSs found that they developed acute rebound flares after SCS cessation.(21) Another study of oral versus IM methylprednisolone reported relapse and rebound flares in as little as 1 week after steroid discontinuation, with no long-lasting improvement…”
BackgroundSystemic therapy of paediatric atopic dermatitis: An update
Borchard, K., & Orchard, D. C. (2008) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2008.00451_1.x · Cited by 17 · cited 1×
“Another Cochrane review assessed the efficacy and safety of oral steroids in adults and children with an asthma exacerbation.(32) Serious AEs were a primary outcome, and any AE was a secondary outcome.”
BackgroundThe treatment of difficult atopic dermatitis in childhood with oral beclomethasone dipropionate.
Aylett, S., Atherton, D. J., & Preece, M. A. (1992) · PubMed · Cited by 17
Advances in the Diagnosis and Therapeutic Management of Atopic Dermatitis
Vestergaard, C., & Deleuran, M. S. (2014) · Drugs · doi:10.1007/s40265-014-0219-3 · Cited by 16
Systemic treatment of adult atopic dermatitis
Cookson, H., & Smith, C. H. (2012) · Clinical Medicine · doi:10.7861/clinmedicine.12-2-172 · Cited by 16
Recent developments in the treatment of adult atopic dermatitis
Pua, V. S., & Barnetson, R. S. (2006) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2006.00237.x · Cited by 14 · cited 3×
“Another study of oral versus IM methylprednisolone reported relapse and rebound flares in as little as 1 week after steroid discontinuation, with no long-lasting improvement in skin disease regardless of administration.(19) AI.”
BackgroundInfluentialDo some patients with atopic dermatitis require long-term oral steroid therapy?
Sonenthal, K. R., Grammer, L. C., & Patterson, R. (1993) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(93)90208-w · Cited by 11
Immediate and delayed hypersensitivity to corticosteroids
Basedow, S., Eigelshoven, S., & Homey, B. (2011) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2011.07718.x · Cited by 9
Systemic Therapies for Pediatric Atopic Dermatitis: A Review for the Primary Care Physician
Shaw, M. G., Burkhart, C. N., & Morrell, D. S. (2009) · Pediatric Annals · doi:10.3928/00904481-20090622-08 · Cited by 7 · cited 1×
“However, even short-courses are associated with decreased respiratory and peripheral muscle strength.(30) Risk for AEs rises with increasing frequency and cumulative exposure ([1 g).”
BackgroundAn overview on atopic dermatitis in children.
Susac, A., Babić, S., & Lipozenčić, J. (2007) · PubMed · Cited by 4
Metadata
- Authors
- Yu, S. H., Drucker, A. M., Lebwohl, M., & Silverberg, J. I.
- Venue
- Journal of the American Academy of Dermatology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 78
- Issue
- 4
- Pages
- 733-740.e11
- ISSN
- 0190-9622 (ISSN-L)
- OpenAlex
- W2764058764
- Cited by
- 171
- References
- 53
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.